Ventyx Biosciences Inc.

10/15/2024 | Press release | Distributed by Public on 10/15/2024 06:11

Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024